I believe that is the end goal or at the very least a licensing agreement so the royalties come rolling in while big pharma manufacture for us. If we have successful drug candidates we are gonna need a lot of manufacturing capacity to keep up with worldwide demand. Personally im more in favour of licensing agreement rather than a buyout but depends how generous the offer is at the end of the day
RCE Charts, page-941
-
- There are more pages in this discussion • 1,223 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
-0.010(2.02%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| 49.8¢ | 49.8¢ | 46.5¢ | $33.89K | 71.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 101 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 10470 | 2 |
View Market Depth
| Last trade - 14.13pm 13/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |